X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the termination, AC Immune will regain all global rights to the anti-amyloid beta antibody RO5490245 (crenezumab) and the anti-Tau antibody semorinemab. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD).
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: RO5490245
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $418.0 million Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2024
Details:
ACI-35.030 previously named as JNJ-64042056 is the first-in-class anti-pTau vaccine candidate which is being evaluated in phase 1/2 clinical trials for the treatment of Alzheimer’s Disease.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.
Lead Product(s): ACI-24.060
Therapeutic Area: Neurology Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Worldwide Clinical Trials
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, and thereby may reduce or prevent disease progression.
Lead Product(s): ACI-24.060
Therapeutic Area: Neurology Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
Early clinical testing showed that ACI-35.030, a first-in-class anti-pTau vaccine, was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and ePHF species, both of which are closely implicated in AD.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
MABT5102A (crenezumab) is a passive immunotherapy approach in which patients are treated with monoclonal antibodies that specifically recognize Aβ peptides. This humanized antibody uses an IgG4 backbone.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
As previously reported, numerical differences favoring MABT5102A (crenezumab) over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significant.
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: MABT5102A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030, a first-in-class tau vaccine candidate in participants with early Alzheimer’s disease treatment.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Semorinemab (RG6100), an anti-tau monoclonal antibody that targets extracellular tau in the brain, is being evaluated for the potential treatment of Alzheimer's disease (AD).
Lead Product(s): Semorinemab
Therapeutic Area: Neurology Product Name: MTAU9937A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.
Lead Product(s): PD01
Therapeutic Area: Neurology Product Name: PD01
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Affiris
Deal Size: $100.8 million Upfront Cash: $5.0 million
Deal Type: Acquisition July 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
